ROSSARI Stock Overview
Rossari Biotech Limited manufactures and sells specialty chemicals in India and internationally.
Rossari Biotech Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹863.10|
|52 Week High||₹1,619.00|
|52 Week Low||₹795.10|
|1 Month Change||-2.89%|
|3 Month Change||-8.12%|
|1 Year Change||-29.47%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||16.38%|
Recent News & Updates
|ROSSARI||IN Chemicals||IN Market|
Return vs Industry: ROSSARI underperformed the Indian Chemicals industry which returned -2.9% over the past year.
Return vs Market: ROSSARI underperformed the Indian Market which returned -1.6% over the past year.
|ROSSARI Average Weekly Movement||4.4%|
|Chemicals Industry Average Movement||6.7%|
|Market Average Movement||6.9%|
|10% most volatile stocks in IN Market||9.7%|
|10% least volatile stocks in IN Market||4.4%|
Stable Share Price: ROSSARI is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: ROSSARI's weekly volatility (4%) has been stable over the past year.
About the Company
Rossari Biotech Limited manufactures and sells specialty chemicals in India and internationally. It offers home, personal care and performance chemical products, including soap and detergents; inks, paints, and coatings; ceramics and tiles; pulp and papers; cement; and water treatment solutions. The company also provides textile specialty chemicals, such as cotton, polyester, acrylic, wool, silk, nylon, functional finishes, denim, and sustainable solutions; and pet grooming products, which include natural pet shampoos, powders, deodorants, sprays, creams, and floor washing liquids under the Lozalo, Hunger Fills, and Sniffy brand names.
Rossari Biotech Fundamentals Summary
|ROSSARI fundamental statistics|
Is ROSSARI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ROSSARI income statement (TTM)|
|Cost of Revenue||₹11.05b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||17.74|
|Net Profit Margin||6.59%|
How did ROSSARI perform over the long term?See historical performance and comparison
0.06%Current Dividend Yield
Does ROSSARI pay a reliable dividends?See ROSSARI dividend history and benchmarks
|Rossari Biotech dividend dates|
|Ex Dividend Date||Jul 07 2022|
|Dividend Pay Date||Aug 14 2022|
|Days until Ex dividend||14 days|
|Days until Dividend pay date||52 days|
Does ROSSARI pay a reliable dividends?See ROSSARI dividend history and benchmarks
Is ROSSARI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ROSSARI?
Other financial metrics that can be useful for relative valuation.
|What is ROSSARI's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does ROSSARI's PE Ratio compare to its peers?
|ROSSARI PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
Price-To-Earnings vs Peers: ROSSARI is expensive based on its Price-To-Earnings Ratio (48.5x) compared to the peer average (42.8x).
Price to Earnings Ratio vs Industry
How does ROSSARI's PE Ratio compare vs other companies in the Indian Chemicals Industry?
Price-To-Earnings vs Industry: ROSSARI is expensive based on its Price-To-Earnings Ratio (48.5x) compared to the Indian Chemicals industry average (16.6x)
Price to Earnings Ratio vs Fair Ratio
What is ROSSARI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||48.5x|
|Fair PE Ratio||29.3x|
Price-To-Earnings vs Fair Ratio: ROSSARI is expensive based on its Price-To-Earnings Ratio (48.5x) compared to the estimated Fair Price-To-Earnings Ratio (29.3x).
Share Price vs Fair Value
What is the Fair Price of ROSSARI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ROSSARI (₹863.1) is trading above our estimate of fair value (₹813.46)
Significantly Below Fair Value: ROSSARI is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: ROSSARI is poor value based on its PEG Ratio (1.5x)
Discover undervalued companies
How is Rossari Biotech forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ROSSARI's forecast earnings growth (32.4% per year) is above the savings rate (6.7%).
Earnings vs Market: ROSSARI's earnings (32.4% per year) are forecast to grow faster than the Indian market (17.3% per year).
High Growth Earnings: ROSSARI's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ROSSARI's revenue (19.1% per year) is forecast to grow faster than the Indian market (11.5% per year).
High Growth Revenue: ROSSARI's revenue (19.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ROSSARI's Return on Equity is forecast to be high in 3 years time (22.1%)
Discover growth companies
How has Rossari Biotech performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ROSSARI has high quality earnings.
Growing Profit Margin: ROSSARI's current net profit margins (6.6%) are lower than last year (11.3%).
Past Earnings Growth Analysis
Earnings Trend: ROSSARI's earnings have grown significantly by 25.9% per year over the past 5 years.
Accelerating Growth: ROSSARI's earnings growth over the past year (21.8%) is below its 5-year average (25.9% per year).
Earnings vs Industry: ROSSARI earnings growth over the past year (21.8%) underperformed the Chemicals industry 29.6%.
Return on Equity
High ROE: ROSSARI's Return on Equity (12.1%) is considered low.
Discover strong past performing companies
How is Rossari Biotech's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: ROSSARI's short term assets (₹6.1B) exceed its short term liabilities (₹2.9B).
Long Term Liabilities: ROSSARI's short term assets (₹6.1B) exceed its long term liabilities (₹1.6B).
Debt to Equity History and Analysis
Debt Level: ROSSARI has more cash than its total debt.
Reducing Debt: ROSSARI's debt to equity ratio has reduced from 41.2% to 1% over the past 5 years.
Debt Coverage: ROSSARI's debt is well covered by operating cash flow (348.4%).
Interest Coverage: ROSSARI's interest payments on its debt are well covered by EBIT (10.7x coverage).
Discover healthy companies
What is Rossari Biotech current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: ROSSARI's dividend (0.058%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.44%).
High Dividend: ROSSARI's dividend (0.058%) is low compared to the top 25% of dividend payers in the Indian market (1.93%).
Stability and Growth of Payments
Stable Dividend: ROSSARI is not paying a notable dividend for the Indian market, therefore no need to check if payments are stable.
Growing Dividend: ROSSARI is not paying a notable dividend for the Indian market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: ROSSARI is not paying a notable dividend for the Indian market.
Cash Payout to Shareholders
Cash Flow Coverage: ROSSARI is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sunil Chari (56 yo)
Mr. Sunil Srinivasan Chari serves as a Managing Director of Rossari Biotech Limited since September 26, 2019 and serves as its Director since 2009. He is a co-founder of Rossari Biotech Limited in 2003. He...
CEO Compensation Analysis
Compensation vs Market: Sunil's total compensation ($USD115.24K) is below average for companies of similar size in the Indian market ($USD342.82K).
Compensation vs Earnings: Sunil's compensation has been consistent with company performance over the past year.
Experienced Management: ROSSARI's management team is considered experienced (2.6 years average tenure).
Experienced Board: ROSSARI's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Rossari Biotech Limited's employee growth, exchange listings and data sources
- Name: Rossari Biotech Limited
- Ticker: ROSSARI
- Exchange: NSEI
- Founded: 2003
- Industry: Specialty Chemicals
- Sector: Materials
- Implied Market Cap: ₹47.395b
- Shares outstanding: 55.06m
- Website: https://www.rossari.com
Number of Employees
- Rossari Biotech Limited
- 201 A & B, Akruti Corporate Park
- 2nd Floor
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/22 00:00|
|End of Day Share Price||2022/06/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.